- Home
- ARGX vs IR Comparison
ARGX vs IR Comparison
Compare ARGX & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- IR
- Stock Information
- Founded
- ARGX 2008
- IR 1859
- Country
- ARGX Netherlands
- IR United States
- Employees
- ARGX N/A
- IR N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- IR Industrial Machinery/Components
- Sector
- ARGX Health Care
- IR Industrials
- Exchange
- ARGX Nasdaq
- IR Nasdaq
- Market Cap
- ARGX 35.3B
- IR 34.2B
- IPO Year
- ARGX 2017
- IR N/A
- Fundamental
- Price
- ARGX $573.26
- IR $81.60
- Analyst Decision
- ARGX Strong Buy
- IR Buy
- Analyst Count
- ARGX 20
- IR 10
- Target Price
- ARGX $698.22
- IR $97.80
- AVG Volume (30 Days)
- ARGX 493.8K
- IR 3.5M
- Earning Date
- ARGX 05-08-2025
- IR 05-01-2025
- Dividend Yield
- ARGX N/A
- IR 0.10%
- EPS Growth
- ARGX N/A
- IR 0.50
- EPS
- ARGX 15.94
- IR 2.02
- Revenue
- ARGX $2,643,062,000.00
- IR $7,281,700,000.00
- Revenue This Year
- ARGX $61.64
- IR $6.80
- Revenue Next Year
- ARGX $32.00
- IR $4.85
- P/E Ratio
- ARGX $32.97
- IR $40.41
- Revenue Growth
- ARGX 82.13
- IR 5.27
- 52 Week Low
- ARGX $359.37
- IR $65.61
- 52 Week High
- ARGX $678.21
- IR $106.03
- Technical
- Relative Strength Index (RSI)
- ARGX 45.96
- IR 55.04
- Support Level
- ARGX $570.00
- IR $79.46
- Resistance Level
- ARGX $584.90
- IR $82.97
- Average True Range (ATR)
- ARGX 14.55
- IR 1.34
- MACD
- ARGX 0.82
- IR -0.15
- Stochastic Oscillator
- ARGX 66.03
- IR 36.21
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.